OPKO HEALTH INC (OPK) Stock Price & Overview
NASDAQ:OPK • US68375N1037
Current stock price
The current stock price of OPK is 1.19 USD. Today OPK is up by 2.59%. In the past month the price decreased by -1.65%. In the past year, price decreased by -31.61%.
OPK Key Statistics
- Market Cap
- 903.293M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.30
- Dividend Yield
- N/A
OPK Stock Performance
OPK Stock Chart
OPK Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OPK. When comparing the yearly performance of all stocks, OPK is a bad performer in the overall market: 84.77% of all stocks are doing better.
OPK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OPK. OPK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
OPK Earnings
On February 26, 2026 OPK reported an EPS of -0.04 and a revenue of 148.50M. The company beat EPS expectations (42.24% surprise) and beat revenue expectations (5.21% surprise).
OPK Forecast & Estimates
11 analysts have analysed OPK and the average price target is 3.63 USD. This implies a price increase of 205% is expected in the next year compared to the current price of 1.19.
For the next year, analysts expect an EPS growth of 8.62% and a revenue growth -7.41% for OPK
OPK Groups
Sector & Classification
OPK Financial Highlights
Over the last trailing twelve months OPK reported a non-GAAP Earnings per Share(EPS) of -0.3. The EPS decreased by -42.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.68% | ||
| ROE | -17.8% | ||
| Debt/Equity | 0.27 |
OPK Ownership
OPK Latest News, Press Relases and Analysis
OPK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.5 | 96.853B | ||
| CI | THE CIGNA GROUP | 8.55 | 70.413B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 92.56 | 24.843B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.59 | 21.941B | ||
| LH | LABCORP HOLDINGS INC | 14.44 | 21.737B | ||
| GH | GUARDANT HEALTH INC | N/A | 11.214B | ||
| DVA | DAVITA INC | 10.66 | 10.068B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 27.62 | 7.415B | ||
| HIMS | HIMS & HERS HEALTH INC | 45.36 | 5.646B | ||
| CHE | CHEMED CORP | 16.57 | 5.534B | ||
| RDNT | RADNET INC | 78.04 | 4.805B | ||
| OPCH | OPTION CARE HEALTH INC | 15.36 | 4.582B | ||
| HNGE | HINGE HEALTH INC-A | 23.31 | 3.542B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OPK
Company Profile
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,275 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Company Info
IPO: 1995-11-02
OPKO HEALTH INC
4400 Biscayne Blvd.
Miami FLORIDA 33137 US
CEO: Phillip Frost
Employees: 2275
Phone: 13055754181
OPKO HEALTH INC / OPK FAQ
Can you describe the business of OPKO HEALTH INC?
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,275 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
What is the stock price of OPKO HEALTH INC today?
The current stock price of OPK is 1.19 USD. The price increased by 2.59% in the last trading session.
Does OPK stock pay dividends?
OPK does not pay a dividend.
What is the ChartMill technical and fundamental rating of OPK stock?
OPK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does OPKO HEALTH INC belong to?
OPKO HEALTH INC (OPK) operates in the Health Care sector and the Health Care Providers & Services industry.
Should I buy OPK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OPK.